- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Harris & Harris Group, Inc. (Nasdaq:TINY) notes that Metabolon, Inc. announced it has successfully raised $13.1 million in a Series D round of financing. New investor, Keating Capital, Inc., joined existing investors, Harris & Harris Group, Sevin Rosen Funds, Aurora Funds, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners in the round. The proceeds from this financing are expected to support further growth of the company's global biochemical profiling services and ongoing development of its oncology diagnostic product portfolio. Harris & Harris Group participated in the Series D financing with an investment of $1.5 million. This investment brings Harris & Harris Group's total investment at cost in Metabolon to $6 million. Metabolon's press release may be accessed at www.metabolon.com/news/PressReleases.aspx?year=2011&open=082911#082911_span.
About Harris & Harris Group
Harris & Harris Group is a publicly traded venture capital company that invests in nanotechnology and microsystems.
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2010, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references to the websites www.HHVC.com and www.metabolon.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the content of third party websites.
For more information, please click here
DANIEL B. WOLFE
TEL. NO. (212) 582-0900
Copyright © GlobeNewswire, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
BESSTECH Announces $250K Investment from Eastern New York Angels : Funding will accelerate commercialization of BESSTECH’s innovative lithium-ion battery electrode technology and enable hiring of key personnel May 13th, 2015
Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015
Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015